BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gao Y, Zheng A, Zhu X, Song J, Xue Q. Clinical benefit from afatinib in an advanced squamous cell lung carcinoma patient harboring HER2 S310Y mutation: a case report. Onco Targets Ther 2018;11:8705-10. [PMID: 30584328 DOI: 10.2147/OTT.S182812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Zeng J, Ma W, Young RB, Li T. Targeting HER2 genomic alterations in non-small cell lung cancer. Journal of the National Cancer Center 2021;1:58-73. [DOI: 10.1016/j.jncc.2021.04.001] [Reference Citation Analysis]
2 Ralki M, Maes B, Pat K, Wynants J, Cuppens K. Triple Trouble: A Case of Multiple Resistance Mechanisms after First Generation EGFR-TKI in NSCLC. Case Rep Oncol 2019;12:625-30. [PMID: 31543779 DOI: 10.1159/000502214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lin L, Ge H, Yan Z, Wang G, Wu X, Lv D. Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report. Onco Targets Ther 2019;12:10897-902. [PMID: 31849493 DOI: 10.2147/OTT.S228726] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
4 Santos ES, Hart L. Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib. Onco Targets Ther 2020;13:9305-21. [PMID: 33061419 DOI: 10.2147/OTT.S250446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]